Measurement of 208 Pb ( n , γ ) 209 Pb Maxwellian averaged neutron capture cross section

The doubly magic 208Pb nucleus is a bottleneck at the termination of the s-process path due to its very low neutron capture cross section. This cross section is also important for the decomposition ofs,r processes and U/Th radiogenic decay contributions to the Pb-Bi solar abundances. The 208Pb(n,γ ) 209Pb cross section was measured at the Soreq Applied Research Accelerator Facility Phase I using an intense quasi-Maxwellian neutron source produced by irradiation of the liquid-lithium target with a 1.5-mA continuous-wave proton beam at 1.94 MeV. The cross section was measured by counting the β activity from the irradiated lead target. The measurement allowed us to evaluate the Maxwellian averaged cross section (MACS) at 30 keV obtaining a value of 0.33(2) mb. This has been compared with the earlier activation and time-of-flight measurements found in the literature. The MACS cross-sectional value of the 63Cu(n,γ ) 64Cu reaction was determined in the same experiment and is compared to a recent published value.EC NeutAndalus (FP7-PEOPLE-2012-CIG No. 334315

The s-process in the Nd-Pm-Sm region: Neutron activation of 147Pm

The Nd-Pm-Sm branching is of interest for the study of the s-process, related to the production of heavy elements in stars. As 148Sm and 150Sm are s-only isotopes, the understanding of the branching allows constraining the s-process neutron density. In this context the key physics input needed is the cross section of the three unstable nuclides in the region: 147Nd (10.98 d half-life), 147Pm (2.62 yr) and 148Pm (5.37 d). This paper reports on the activation measurement of 147Pm, the longest-lived of the three nuclides. The cross section measurement has been carried out by activation at the SARAF LiLiT facility using a 56(2) μg target. Compared to the single previous measurement of 147Pm, the measurement presented herein benefits from a target 2000 times more massive. The resulting Maxwellian Averaged Cross Section (MACS) to the ground and metastable states in 148Pm are 469(50) mb and 357(27) mb. These values are 41% higher (to the ground state) and 15% lower (to the metastable state) than the values reported so far, leading however to a total cross section of 826(107) mb consistent within uncertainties with the previous result and hence leaving unchanged the previous calculation of the s-process neutron density.University of Seville [FPA2013-45083P, FPA2014-53290-C2-2-P, FPA2016-77689-C2-1-R]EC FP7 projects NeutAndalus [334315]CHANDA [605203

The Soreq Applied Research Accelerator Facility (SARAF) - Overview, Research Programs and Future Plans

The Soreq Applied Research Accelerator Facility (SARAF) is under construction in the Soreq Nuclear Research Center at Yavne, Israel. When completed at the beginning of the next decade, SARAF will be a user facility for basic and applied nuclear physics, based on a 40 MeV, 5 mA CW proton/deuteron superconducting linear accelerator. Phase I of SARAF (SARAF-I, 4 MeV, 2 mA CW protons, 5 MeV 1 mA CW deuterons) is already in operation, generating scientific results in several fields of interest. The main ongoing program at SARAF-I is the production of 30 keV neutrons and measurement of Maxwellian Averaged Cross Sections (MACS), important for the astrophysical s-process. The world leading Maxwellian epithermal neutron yield at SARAF-I ($5\times 10^{10}$ epithermal neutrons/sec), generated by a novel Liquid-Lithium Target (LiLiT), enables improved precision of known MACSs, and new measurements of low-abundance and radioactive isotopes. Research plans for SARAF-II span several disciplines: Precision studies of beyond-Standard-Model effects by trapping light exotic radioisotopes, such as $^6$He, $^8$Li and $^{18,19,23}$Ne, in unprecedented amounts (including meaningful studies already at SARAF-I); extended nuclear astrophysics research with higher energy neutrons, including generation and studies of exotic neutron-rich isotopes relevant to the rapid (r-) process; nuclear structure of exotic isotopes; high energy neutron cross sections for basic nuclear physics and material science research, including neutron induced radiation damage; neutron based imaging and therapy; and novel radiopharmaceuticals development and production. In this paper we present a technical overview of SARAF-I and II, including a description of the accelerator and its irradiation targets; a survey of existing research programs at SARAF-I; and the research potential at the completed facility (SARAF-II).Comment: 32 pages, 31 figures, 10 tables, submitted as an invited review to European Physics Journal

93Zr developments at the Heavy Ion Accelerator Facility at ANU

The long-lived radionuclide 93Zr t1/2 = (1.61 +- 0.05) Ma plays an important role in nuclear astrophysics and nuclear technology. In stellar environments, it is mainly produced by neutron capture on the stable nuclide 92Zr. On Earth high amounts of radioactive 93Zr are produced in nuclear power plants directly from 235U fission, but also by neutron capture on 92Zr, as Zr-alloys are commonly used as cladding for nuclear fuel rods.This work was supported by the Australian Research Council DP140100136

Accelerator mass spectrometry measurement of the reaction 35Cl(n,γ)36Cl at keV energies

The nuclide 35Cl can act as a minor “neutron poison” in the stellar slow neutron capture process

The liquid-lithium target at the soreq applied research accelerator facility

Franz Käppeler and collaborators showed in the 1980’s that the $$^7$$Li(p, n)$$^7$$Be reaction can be used to produce a flux of neutrons having a stellar-like energy distribution, closely similar to that contributing to the slow (s) neutron capture process in massive stars. The Liquid-Lithium Target (LiLiT) at Phase I of the Soreq Applied Research Accelerator Facility (SARAF) was designed following the same physical principle. Owing to the high proton beam intensity of SARAF and the power dissipation of LiLiT, the facility provided a neutron intensity more than one order of magnitude higher than available with conventional solid Li targets. We review here our first collaboration with Franz Käppeler and his group, the LiLiT design and nuclear astrophysics research accomplished in recent years at the SARAF-LiLiT facility. An outlook to the research program with SARAF Phase II, currently in construction, is presented

Is There a Role for Molecular Testing for Low-Risk Differentiated Thyroid Cancer? A Cost-Effectiveness Analysis

Molecular testing for thyroid nodules has been rapidly developed in recent years, aiming to predict the presence of malignancy and aggressive features. While commonly utilized to predict malignancy, its role in guiding the management approach is still developing. The high cost of genetic tests and long-term sequences of thyroid cancer is limiting to real-life studies. Objective: To evaluate the cost effectiveness of molecular testing for low-risk differentiated thyroid cancer (lrDTC). Methods: We developed a Markovian decision tree model of a simulated lrDTC cohort, comparing two management strategies: (I) Conducting genetic tests (GT)—patients are stratified into three risk groups for distant metastasis by the identified molecular markers: low-, intermediate- and high-risk molecular profile; followed by management accordingly: patients with low-risk will undergo hemithyroidectomy (HT), patients with intermediate-risk will undergo total thyroidectomy (TT), and high-risk patients will undergo TT with central neck dissection; (II) Without genetic tests (wGT)—all patients will undergo HT according to the ATA recommendations for lrDTC. Outcomes were measured as quality-adjusted life years (QALYs) and costs of each strategy. Results: GT was found as cost effective, leading to a gain of 1.7 QALYs with an additional cost of $327 per patient compared to wGT strategy. This yielded an incremental cost-effectiveness ratio of$190 per QALY. Sensitivity analysis demonstrated robust results across the variables’ ranges. The most impactful variable was the benefit from performing TT rather than HT for intermediate to high-risk patients. Conclusions: Our model found that molecular testing for lrDTC is cost-effective, allowing tailored management according to the patient’s personal risk level reflected in the genetic profile, hence improving outcomes

Is There a Role for Molecular Testing for Low-Risk Differentiated Thyroid Cancer? A Cost-Effectiveness Analysis

Molecular testing for thyroid nodules has been rapidly developed in recent years, aiming to predict the presence of malignancy and aggressive features. While commonly utilized to predict malignancy, its role in guiding the management approach is still developing. The high cost of genetic tests and long-term sequences of thyroid cancer is limiting to real-life studies. Objective: To evaluate the cost effectiveness of molecular testing for low-risk differentiated thyroid cancer (lrDTC). Methods: We developed a Markovian decision tree model of a simulated lrDTC cohort, comparing two management strategies: (I) Conducting genetic tests (GT)—patients are stratified into three risk groups for distant metastasis by the identified molecular markers: low-, intermediate- and high-risk molecular profile; followed by management accordingly: patients with low-risk will undergo hemithyroidectomy (HT), patients with intermediate-risk will undergo total thyroidectomy (TT), and high-risk patients will undergo TT with central neck dissection; (II) Without genetic tests (wGT)—all patients will undergo HT according to the ATA recommendations for lrDTC. Outcomes were measured as quality-adjusted life years (QALYs) and costs of each strategy. Results: GT was found as cost effective, leading to a gain of 1.7 QALYs with an additional cost of $327 per patient compared to wGT strategy. This yielded an incremental cost-effectiveness ratio of$190 per QALY. Sensitivity analysis demonstrated robust results across the variables’ ranges. The most impactful variable was the benefit from performing TT rather than HT for intermediate to high-risk patients. Conclusions: Our model found that molecular testing for lrDTC is cost-effective, allowing tailored management according to the patient’s personal risk level reflected in the genetic profile, hence improving outcomes

Measuring neutron capture rates on ILL-produced unstable isotopes (147Pm, 171Tm and 204Tl, and plans for 79Se and 163Ho) for nucleosynthesis studies

Neutron capture cross sections are among the main inputs for nucleosynthesis network calculations. Although well known for the majority of the stable isotopes, this quantity is still unknown for most of the unstable isotopes of interest. A recent collaboration between ILL, PSI, U. Sevilla and IFIC aims at producing the isotopes of interest at ILL, preparing suitable targets at PSI, and measuring their capture cross sections at facilities such as n_TOF/CERN, LiLiT and the Budapest Research Reactor (BRR). This work is focused on the description of the different beams and techniques and shows some highlights of the preliminary results of the capture measurements on 171Tm, 147Pm and 204Tl, along with the future plans for 79Se and 163Ho.Ministerio de Economía y Competitividad FPA2013-45083-P, FPA2014-53290-C2-2-PEurpean Commission 334315, 60520

Stellar

We report on experiments at the Soreq Applied Research Accelerator Facility Liquid-Lithium Target (SARAF-LiLiT) laboratory dedicated to the study of s-process neutron capture reactions. The kW-power proton beam at 1.92 MeV (1-2 mA) from SARAF Phase I yields high-intensity 30 keV quasi-Maxwellian neutrons (3-5 1010 n/s). The high neutron intensity enables Maxwellian averaged cross sections (MACS) measurements of samples with short-lived decay products. Neutron capture reactions on natSe and natCe were investigated by activation in the LiLiT neutron beam and γ-spectrometry measurements of their decay products